Ligand Pharmaceuticals Incorporated (LGND) Q3 2013 Earnings Results

Ligand Pharmaceuticals Beats on EPS, Stock Down 5.76%

Ligand Pharmaceuticals reported a significant EPS beat, which is a positive sign for the company's profitability. However, the stock fell by 5.76%, likely due to the lack of revenue information and guidance, leaving investors uncertain about future performance. The market reaction suggests that investors were looking for more comprehensive data to assess the company's trajectory.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.12	N/A	+90.48%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Management remains optimistic about the company's future prospects. They emphasized the importance of their ongoing initiatives.

Management highlighted the strong performance in EPS despite not providing revenue figures.

They expressed confidence in their ongoing projects and partnerships.

Ligand Pharmaceuticals Beats on EPS, Stock Down 5.76%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Beats on EPS, Stock Down 5.76%

Key numbers

Management commentary